<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30227">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02069717</url>
  </required_header>
  <id_info>
    <org_study_id>DW_FAMI_001</org_study_id>
    <nct_id>NCT02069717</nct_id>
  </id_info>
  <brief_title>Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule)</brief_title>
  <official_title>Multi-center, Prospective, Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule) Add-on to Statin Therapy in Patients Who Have History of Acute Myocardial Infarction and Are Diagnosed With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess the incidence rate of the major adverse
      cardiovascular events (MACE) and safety of fenofibrate (Lipilfen capsule) add-on statin
      therapy in patients who have history of acute myocardial infarction and are diagnosed with
      metabolic syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>The incidence rate of the major adverse cardiovascular events (MACE)</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>cardiac death, MI, re-PCI, CABG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence rate of the major adverse cardiac and cerebrovascular event (MACCE)</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>non-cardiac death, stroke, hospitalization for acute coronary syndrome</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1573</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Not applicable-observational study</arm_group_label>
    <description>Not applicable-observational study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Not applicable-observational study</intervention_name>
    <arm_group_label>Not applicable-observational study</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects aged more than 20 with history of acute myocardial infarction and diagnosed with
        metabolic syndrome
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients &gt;20 years of age.

          -  history of acute myocardial infarction

          -  metabolic syndrome diagnosis

        Exclusion Criteria:

          -  current liver disease or AST or ALT greater than 3 times the upper limit of reference
             range

          -  pre-existing gallbladder disease

          -  moderate to severe renal disorder (serum creatinine &gt;2.5mg/dL)

          -  pancreatitis diagnosis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chonnam national university hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung Ho Jeong, MD, PhD</last_name>
      <email>shj@daewoong.co.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 20, 2014</lastchanged_date>
  <firstreceived_date>February 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
